Concept explainers
Adapting to Host Defenses Surface proteins called HLAs allow white blood cells to detect HIV particles and fight an infection. In a recent study, scientists tested whether HIV is adapting to this host defense. They did so by looking at the frequency of a specific mutation (1135X) in HIV. This “escape mutation” helps the virus avoid detection by a version of the HLA protein (HLA-B*51) that is common in some regions of the world, but not in others. FIGURE 20.19 shows the percentage of HIV-positive people who had HIV with the 1135X mutation. Data were collected at medical centers from several parts of the world.
FIGURE 20.19 Regional variation in the frequency of the 1135X escape mutation among HIV-positive people. For each region, pink bars represent the percentage of people whose blood cells have HLA-B*51. and thus cannot detect 1135X mutants. Blue bars represent the percentage of people with other versions of the HLA protein. These people have blood cells that can detect and fight HIV even if it has the 1135X mutation.
1. What percentage of people with H LA-B*51 in Vancouver had HIV with the escape mutation for this protein?
Want to see the full answer?
Check out a sample textbook solutionChapter 20 Solutions
Biology: The Unity and Diversity of Life (MindTap Course List)
- The envelope protein gp120 (Glycoprotein 120) is required for the attachment of the HIV virus to CD 4 receptors of target host cells. Identify the immune cells that consist of CD 4 receptors?arrow_forwardHuman genome-wide genetic association (GWAS) studies have identified several genetic polymorphisms that contribute to HIV control, and the rate of disease progression to AIDS. Which two immune cell subsets are implicated by these data as important regulators of HIV replication and the rate of disease progression?arrow_forward1) 286 individuals were newly diagnosed with Human Immunodeficiency Virus in 2018 in Minnesota. Of these individuals, 76% were male. HIV is an enveloped, ssRNA virus_ Baltimore classification VI. This virus targets CD4+ cells. CD4 refers to a glycoprotein which serves as a co-receptor for T-cells, located on T-helper and T-reg immune cells. a) What part of the HIV virus allows for specificity to CD4+ cells?arrow_forward
- One strategy for vaccine development currently under investigation is the use of pathogen-derived T cell epitopes as a component of the vaccine. For viral pathogens, implementing this strategy involves scanning the predicted amino acid sequences of the viral proteins for likely peptide epitopes that would bind to MHC class I and MHC class II molecules. In addition to the complication of MHC sequence polymorphism in the human population, another complication of this strategy for peptide epitopes that would bind to MHC class II proteins is: The importance of viral proteins containing peptides that are cleaved into 8–10 amino acid long fragments. The ability of viruses to mutate their proteins to avoid MHC anchor residue sequences. The fact that long peptides (>13 amino acids) are rapidly degraded in cells. The fact that MHC class II proteins are intrinsically stable, even in the absence of binding to a peptide. The absence of defined sequence motifs that predict peptide binding to…arrow_forwardWhich of the following is the most likely explanation for an individual who lacks CCR5 as a result of a homozygous defect in the CCR5 gene becoming infected with HIV? a. The mutated CCR5 genes reverted to the normal form, rendering macrophages susceptible to macrophagetropic HIV variants. b. The macrophage-tropic HIV variant entered host cells using CD4 alone. c. The viral nucleic acid alone was taken up by cells, as in cell transformation by bacterial DNA. d. The individual had received a transplant of HIV-infected cells expressing normal CCR5. e. The primary infection involved a lymphocyte-tropic strain of HIV that used CXCR4 as its co-receptor.arrow_forwardA number of vaccines against the SARS-CoV-2 virus (which causes COVID) are currently in use. Based on what you learned about the immune system and vaccines, this vaccine should provide immunity against this virus because: a Vaccines bind to the variable region of immunoglobulins, and prevent the antibody-antigen interactions required for the virus to be released from cells. b Vaccines elicit a primary immune response and resulting memory cells specific to the viral antigens can persist in the body c Vaccines block clonal expansion of helper T cells which are required for the virus to infect cells d Vaccines block the production of cytokines e Vaccines induce cytotoxic T cells to produce antibodies specific to antigens on the virusarrow_forward
- The experiment shown in thefigure below uses two strains of mice that differ in their MHC genes. Strain A is H-2a and Strain B is H-2b. Mice of each strain are infected with the virus LCMV, and T cells are isolated at day 8 post-infection. These T cells are mixed with target cells that express either H-2a or H-2b; in each case, the target cells are either uninfected or infected with LCMV. After a four-hour incubation of T cells with target cells, the percentage of target cells lysed by the T cells is shown in the graph. The explanation for the results of this experiment is: Mice of strain B do not make a T cell response to LCMV. Mice of strain A make a more robust T cell response to LCMV than mice of strain B. Target cells that express H-2b cannot be infected with LCMV. T cells from mice of strain A only recognize viral peptides on target cells expressing H-2a. LCMV peptides do not bind to MHC class I molecules from H-2b mice.arrow_forwardCan you compare and contrast the infection process of influenza and HIV? What are the specific molecules on the surface of each virus that directly interacts with the respective cellular receptor molecule? What is/are the specific molecules on the surface of the respective target cells that serve as the cellular receptors for these viruses respectively?arrow_forwardIt is observed that there is a decrease in the antibody level against Wuhan strain of virus but an increase in antibodies against the Beta variant and Omicron variant. explain how this occurred?arrow_forward
- The diagram below shows the Covid-19 virus with its spike protein. It also shows the area on the spike protein which binds to the ACE2 receptor (receptor binding domain). Corona Virus Receptor Binding Domain (RBD) Spike Protein In order to get into a cell, the Covid-19 virus needs to bind to the ACE2 receptor. Once bound it is brought into the cell. These receptors are found on cells making up various tissues (oral and nasal mucosa, nasopharynx, lung, stomach, small intestine, colon, skin, lymph nodes, thymus, bone marrow, spleen, liver, kidney, and brain). The symptoms for Covid-19 are linked to the tissue cells the virus infects. To the right is a diagram showing the biding of the spike protein to the ACE2 receptor. SARS-COV-2 Spike (S) Host Cell ACE2 acerarrow_forwardAn outbreak of Ebola between 2014 and 2016 resulted in 28,616 cases and 11,310 deaths in Guinea, Liberia and Sierra Leone. An additional 36 cases and 15 deaths were reported outside these 3 countries. This deadly disease urged the need for extensive research on Ebola to better understand and treat the disease and prevent future outbreaks. Ebola is a - SSRNA virus. What does this mean for how it is converted into proteins? Does this virus require additional machinery to be infectious? Can you hypothesize based on how it replicates in the cell what scientists might hope to target for treatment or prevention of Ebola?arrow_forwardFrom: "Towards a universal flu vaccine" Researchers are trying to create a universal influenza vaccine - one that can confer %3D immunity to all, or nearly all, strains of influenza virus. The universal vaccine will target a stable antigen that is present on all influenza viruses that does not readily mutate to different forms. The target researchers are focusing on as a universal stable antigen is on the... The H spike head. O H spike neck N spike O Viral envelopearrow_forward
- Human Physiology: From Cells to Systems (MindTap ...BiologyISBN:9781285866932Author:Lauralee SherwoodPublisher:Cengage Learning